Infectious disease
This deal with BARDA and the DoD supports continuing the manufacturing in order for it to be immediately available in the U.S. if the clinical trials are successful.
Novavax said the funding will allow the company to participate in Operation Warp Speed, the government’s program that has a goal of supporting the development of hundreds of millions of vaccine doses by 2021.
As countries reopen businesses and move toward normalcy, emerging biotech companies in the U.S. and Europe have encountered a mixed bag of experiences.
As of June 29, there were 13 vaccines against COVID-19 in human clinical trials.
In a forthcoming paper, 239 scientists from more than 30 countries are pushing the World Health Organization to pay more attention to the possible airborne spread of SARS-CoV-2.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 6, 2020.
Emergent will handle contract development and manufacturing (CDMO) services in a deal that is valued at about $480 million for the first two years.
Regeneron Pharmaceuticals, with the U.S. National Institute of Allergy and Infectious Diseases (NIAID), is launching Phase III trials of REGN-COV2, the company’s two-antibody cocktail for the treatment and prevention of COVID-19.
It’s not clear how long the trial will be delayed, but according to a report by STAT, it may still begin in July.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 3, 2020.
PRESS RELEASES